Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ATHE
- Price
- 4.20
- Stock movement up
- +0.07 (1.39%)
- Company name
- Alterity Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 78.27M
- Ent value
- 71.06M
- Price/Sales
- 16.62
- Price/Book
- 5.67
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -23.53%
- 1 year return
- 249.32%
- 3 year return
- -6.66%
- 5 year return
- -28.40%
- 10 year return
- -23.07%
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ATHE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 16.62 |
| Price to Book | 5.67 |
| EV to Sales | 15.09 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 15.35M |
| EPS (TTM) | -2.92 |
| FCF per share (TTM) | -1.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.71M |
| Gross profit (TTM) | 4.48M |
| Operating income (TTM) | -25.74M |
| Net income (TTM) | -23.24M |
| EPS (TTM) | -2.92 |
| EPS (1y forward) | -0.86 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.13% |
| Operating margin (TTM) | -546.40% |
| Profit margin (TTM) | -493.35% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 12.64M |
| Net receivables | 4.04M |
| Total current assets | 19.04M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 619.08K |
| Total assets | 19.22M |
| Accounts payable | 581.14K |
| Short/Current long term debt | 159.04K |
| Total current liabilities | 5.37M |
| Total liabilities | 5.43M |
| Shareholder's equity | 13.80M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.42M |
| Capital expenditures (TTM) | 6.28K |
| Free cash flow (TTM) | -12.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -168.41% |
| Return on Assets | -120.88% |
| Return on Invested Capital | -167.11% |
| Cash Return on Invested Capital | -93.32% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.06 |
| Daily high | 5.11 |
| Daily low | 4.90 |
| Daily Volume | 8K |
| All-time high | 765.00 |
| 1y analyst estimate | 11.00 |
| Beta | 0.51 |
| EPS (TTM) | -2.92 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ATHE | S&P500 | |
| Current price drop from All-time high | -99.33% | -1.46% |
| Highest price drop | -99.86% | -56.47% |
| Date of highest drop | 25 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -86.80% | -10.99% |
| Avg time to new high | 1126 days | 12 days |
| Max time to new high | 5623 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
78.27M
Marketcap category
Small-cap
Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Employees
10
Investor relations
-
SEC filings
CEO
Geoffrey Paul Kempler
Country
USA
City
Melbourne
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page